Affinia Therapeutics Advances AFTX-201 for BAG3 DCM
WALTHAM, Mass., April 28, 2026 Affinia Therapeutics has announced new progress for AFTX-201, its lead investigational gene therapy for...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WALTHAM, Mass., April 28, 2026 Affinia Therapeutics has announced new progress for AFTX-201, its lead investigational gene therapy for...
Waltham, Massachusetts, USA, April 6, 2026 Health Canada Approval Marks Key Clinical Milestone In a significant development for cardiovascular...
